Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 15;12(1):2154115.
doi: 10.1080/2162402X.2022.2154115. eCollection 2023.

Cellular senescence enhances adaptive anticancer immunosurveillance

Ines Marin  1 , Manuel Serrano  1   2 , Federico Pietrocola  3
Affiliations

Cellular senescence enhances adaptive anticancer immunosurveillance

Ines Marin et al. Oncoimmunology. .

Abstract

Cancer therapy often induces senescence in some cancer cells. Senescent cells, due to their profoundly altered biology, may conceivably interact with the adaptive immune system in novel ways that may boost cancer immunosurveillance, triggering the clearance of both senescent and non-senescent neoplastic cells. In this regard, we have recently reported that senescent cancer cells exhibit potent antigenicity and adjuvanticity and can elicit strong CD8+ T cell-dependent anticancer effects when used as vaccination agents.

Keywords: Aging; immunopeptidome; inflammation; interferon; vaccination.

PubMed Disclaimer

Conflict of interest statement

M.S. is shareholder of Senolytic Therapeutics, Life Biosciences, Rejuveron Senescence Therapeutics and Altos Labs, and is advisor of Rejuveron Senescence Therapeutics and Altos Labs. The funders had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation.

Figures

Figure 1.
Figure 1.
Senescent cancer cells promote superior TIL activation. Anti-cancer immunosurveillance relies upon the efficient activation of the cancer-immunity cycle. Senescent cancer cells boost the ignition of this process via different modalities that include (i) the enhanced expression of MHC-I and MHC-I associated antigens; (ii) the secretion of immunostimulatory alarmins and (iii) the efficient transfer of antigens to Dendritic Cells (DCs), which in turn prime and unleash the cytotoxic action of TILs against tumor cells.
See this image and copyright information in PMC

References

    1. Marin I, Boix O, Garcia-Garijo A, Sirois I, Caballe A, Zarzuela E, Ruano I, Stephan-Otto Attolini C, Prats N, Lopez-Dominguez JA, et al. Cellular senescence is immunogenic and promotes anti-tumor immunity. Cancer Discov. 2022. doi:10.1158/2159-8290.CD-22-0523. - DOI - PMC - PubMed
    1. Chen DS, Mellman I.. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–3. doi:10.1016/j.immuni.2013.07.012. - DOI - PubMed
    1. Vanmeerbeek I, Sprooten J, De Ruysscher D, Tejpar S, Vandenberghe P, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L, et al. Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. Oncoimmunology. 2020;9(1):1703449. doi:10.1080/2162402X.2019.1703449. - DOI - PMC - PubMed
    1. Gorgoulis V, Adams PD, Alimonti A, Bennett DC, Bischof O, Bishop C, Campisi J, Collado M, Evangelou K, Ferbeyre G, et al. Cellular senescence: defining a path forward. Cell. 2019;179(4):813–827. doi:10.1016/j.cell.2019.10.005. - DOI - PubMed
    1. Sprooten J, Garg AD. Type I interferons and endoplasmic reticulum stress in health and disease. Int Rev Cell Mol Biol. 2020;350:63–118. doi:10.1016/bs.ircmb.2019.10.004. - DOI - PMC - PubMed

Publication types